The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 26, 2018
Filed:
Jul. 20, 2016
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Irving H. Fox, Wellesley, MA (US);
Catherine Scholz, Woburn, MA (US);
Assignee:
MILLENNIUM PHARMACEUTICALS, INC., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/26 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/18 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/26 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 39/39591 (2013.01); A61K 47/183 (2013.01); C07K 16/2839 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract
Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human α4β7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.